Skip to main content
. 2025 Aug 12;16:1629473. doi: 10.3389/fimmu.2025.1629473

Figure 10.

Box plots showing anti-Spike IgG activity levels at one and six months after vaccination with BNT162b2 and mRNA-1273 for different groups. Groups include Healthy Control, Multiple Myeloma, non-MM hematological, and Solid, with doses ranging from two to four. Geometric means, confidence intervals, and statistical significance are indicated. The data is split into groups for one month (top row) and six months (bottom row) post-vaccination.

Anti-SARS-CoV-2 spike IgG avidity post vaccination in serum samples from cancer and healthy cohorts within different vaccine groups. Comparison of serum anti-spike IgG avidity in healthy, multiple myeloma, non-MM hematological cancer and solid cancer cohorts within different vaccine groups 1-month (A) and 6-months (B) post-vaccination. Anti-spike IgG levels were presented as Geometric Mean with 95% confidence intervals (95% CI). Box plots show median (horizontal bar), the first and third quartiles. Differences assessed by non-parametric Wilcoxon rank sum test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.